Basit öğe kaydını göster

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

dc.contributor.authorArena, Francis
dc.contributor.authorAndre, Fabrice
dc.contributor.authorO'Regan, Ruth
dc.contributor.authorToi, Masakazu
dc.contributor.authorXu, Binghe
dc.contributor.authorJerusalem, Guy
dc.contributor.authorMasuda, Norikazu
dc.contributor.authorWilks, Sharon
dc.contributor.authorIsaacs, Claudine
dc.contributor.authorYap, Yoon-Sim
dc.contributor.authorPapai, Zsuzsanna
dc.contributor.authorLang, Istvan
dc.contributor.authorArmstrong, Anne
dc.contributor.authorLerzo, Guillermo
dc.contributor.authorWhite, Michelle
dc.contributor.authorShen, Kunwei
dc.contributor.authorLitton, Jennifer
dc.contributor.authorChen, David
dc.contributor.authorZhang, Yufen
dc.contributor.authorAli, Shyanne
dc.contributor.authorTaran, Tetiana
dc.contributor.authorGianni, Luca
dc.contributor.authorOzguroglu, Mustafa
dc.date.accessioned2021-03-06T21:33:49Z
dc.date.available2021-03-06T21:33:49Z
dc.date.issued2014
dc.identifier.citationAndre F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., Masuda N., Wilks S., Arena F., Isaacs C., et al., "Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial", LANCET ONCOLOGY, cilt.15, ss.580-591, 2014
dc.identifier.issn1470-2045
dc.identifier.othervv_1032021
dc.identifier.otherav_ff3a7f03-b1b7-4ab1-b625-9916f35844cf
dc.identifier.urihttp://hdl.handle.net/20.500.12627/166870
dc.identifier.urihttps://doi.org/10.1016/s1470-2045(14)70138-x
dc.description.abstractBackground Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.titleEverolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
dc.typeMakale
dc.relation.journalLANCET ONCOLOGY
dc.contributor.departmentInstitut National de la Sante et de la Recherche Medicale (Inserm) , ,
dc.identifier.volume15
dc.identifier.issue6
dc.identifier.startpage580
dc.identifier.endpage591
dc.contributor.firstauthorID44077


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster